Company Overview
CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing therapeutics designed to address illnesses driven by inflammatory and immunologic processes as well as direct cellular damage. The firm functions within the broader Healthcare sector, specifically classified under the Biotechnology industry, which typically involves high-risk, high-reward research and development cycles focused on novel drug candidates. As of the latest data, the company maintains a market capitalization of $8.96M while employing a workforce of 16 individuals. The combination of an $8.96M market cap and reported annual revenue of N/A indicates that CalciMedica is a micro-cap entity currently prioritizing research and development over commercial scaling, a status often seen in early-stage biotechnology firms that have not yet generated significant commercial sales.
Financial Health
The company reports a net income of $-29,562,000 over the trailing twelve months, while revenue is listed as N/A, creating a substantial gap that reveals a cost structure dominated by research expenses and operational overhead rather than cost of goods sold. EBITDA for the period stands at $-23,075,000, further confirming that the business model is currently cash-intensive with no commercial revenue to offset these heavy development costs. Free cash flow is reported at $-13,020,375, indicating a negative financial flexibility where the company must rely on external capital sources such as cash reserves or financing to fund its operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the absence of commercial sales revenue necessary to generate a positive margin in a traditional manufacturing or sales model. The balance sheet holds $13.02M in cash against $9.70M in debt, suggesting a net positive liquidity position despite the negative equity implied by the valuation metrics. Although the debt-to-equity ratio is listed as N/A due to the company's financial structure, the absolute cash level exceeds the absolute debt level, providing a buffer against short-term obligations. The current ratio is 3.58, a figure that indicates a strong ability to meet short-term liabilities with short-term assets, highlighting a conservative liquidity stance relative to its peers. Return on Equity is -761.0% and Return on Assets is -86.6%, metrics that reveal the company is currently destroying shareholder value per dollar invested, a common characteristic for pre-revenue biotechnology firms burning through capital to advance their clinical pipelines.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A, while the forward P/E is -0.35, a difference that implies the market is valuing the company based on future expectations rather than historical earnings, though the negative forward multiple signals continued anticipated losses. The price-to-book ratio is -1.32, which indicates that the market is pricing the company below its book value, a phenomenon often seen in biotechnology firms where intangible assets like intellectual property are not fully captured on the balance sheet. Price-to-sales and EV/EBITDA metrics are presented as N/A and -0.24 respectively, suggesting that traditional valuation multiples are not applicable given the lack of revenue, while the negative EV/EBITDA reinforces the expectation of future profitability that has not yet materialized. The stock has traded between a 52-week high of $7.20 and a 52-week low of $0.46, placing the current valuation within a wide range that reflects the high volatility typical of small-cap biotech stocks. The beta value of 1.24 indicates that the stock's price volatility is higher than the broader market, moving 24% more than the market average during periods of instability.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the fact that the company has not yet achieved consistent commercial sales to calculate year-over-year growth percentages. Because there is no revenue base to compare, earnings cannot grow faster or slower than revenue in a traditional sense, as the company is in a stage where investment precedes return. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This non-dividend status implies that the company retains all available cash and reinvests earnings strictly into research, development, and clinical trial activities rather than paying out income to investors. The overall growth and income profile is characterized by a complete absence of current income generation and historical growth data, focusing entirely on the potential future value derived from the development of its lead product candidate, Auxora.